Cisen Pharmaceutical Ltd. (603367.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 13.78

From 52W high−46.01%

Volume5.44M

Market capCNY 6.16B

P/E (TTM)14.6x

P/S (TTM)1.9x

Div yield4.06%

Key dataSep 18, 2026

Open

CNY 13.78

From 52W high

−46.01%

Volume

5.44M

Market cap

CNY 6.16B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

7.9x

P/E (TTM)

14.6x

RSI (14)

43.1

MomentumView details →

1D Return

−3.48%

YTD Return

−19.75%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

14.6x

EV/EBITDA

7.9x

EV/Sales

1.6x

P/S (TTM)

1.9x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

51.29%

Net Margin

12.10%

EBITDA Margin

20.73%

ROE (TTM)

6.46%

ROA (TTM)

5.34%

Asset Turnover

0.44x

GrowthView details →

Revenue YoY

−10.07%

EPS YoY

−16.73%

FCF YoY

+82.10%

Revenue CAGR 3Y

−5.38%

EPS CAGR 3Y

+6.50%

EBITDA YoY

—

MomentumView details →

1D Return

−3.48%

YTD Return

−19.75%

1Y Return

−33.46%

RSI (14)

43.1

vs 50D SMA

−4.31%

vs 200D SMA

−12.11%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.65x

Quick Ratio

4.12x

Div Yield

4.06%

Div Rate

CNY 0.56

Div Growth 1Y

−7.84%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.37B

Net Income (TTM)

408.45M

Op. CF (TTM)

601.40M

Latest newsMore news →

Cisen Pharmaceutical announced that it plans to permanently replenish working capital with the remaining balance of RMB 13.0958 million from the "BFS 'blow-fill-seal' integrated aseptic filling production line project" after the project's completion and closing; the matter has been approved by the company's 14th meeting of the fifth board of directors and will be submitted to the 2026 first extraordinary shareholders' meeting for review.5d ago

Shandong Chenxin Pharmaceutical's subsidiary Shandong Chenxin Fodu Pharmaceutical received a drug registration certificate from the National Medical Products Administration for loteprednol etabonate and tobramycin eye drops, the first generic version approved in China.6d ago

Similar companies

China Traditional Chinese Medicine Holdings Co. Limited00570.HK China Shineway Pharmaceutical Group Limited02877.HK 昆药集团600422.SH Amneal Pharmaceuticals, Inc.AMRX CanSino Biologics Inc.06185.HK 华纳药厂688799.SH Find similar companies →

Latest newsMore news →

Cisen Pharmaceutical announced that it plans to permanently replenish working capital with the remaining balance of RMB 13.0958 million from the "BFS 'blow-fill-seal' integrated aseptic filling production line project" after the project's completion and closing; the matter has been approved by the company's 14th meeting of the fifth board of directors and will be submitted to the 2026 first extraordinary shareholders' meeting for review.5d ago Shandong Chenxin Pharmaceutical's subsidiary Shandong Chenxin Fodu Pharmaceutical received a drug registration certificate from the National Medical Products Administration for loteprednol etabonate and tobramycin eye drops, the first generic version approved in China.6d ago